A

1 10-K FILINGS
2 PharmaCorp
3 Consolidated Balance Sheets (USD $)
4 In Millions, except Share data, unless otherwise specified
5
6 ASSETS
7 Cash and cash equivalents
8 Short-term investments
9 Accounts receivable, less allowance for doubtful accounts, 2015—$374; 2014—$226
10 Inventories
11 Taxes and other current assets
12 Assets of discontinued operations and other assets held for sale
13 Total current assets
14 Long-term investments
15 Property, plant and equipment, less accumulated depreciation
16 Goodwill
17 Identifiable intangible assets, less accumulated amortization
18 Taxes and other noncurrent assets
19 Total assets
20
21 LIABILITIES AND EQUITIES
22 Short-term borrowings, including current portion of long-term debt: 2015—$2,449; 2014—
$6
23 Accounts payable
24 Dividends payable
25 Income taxes payable
26 Accrued compensation and related items
27 Other current liabilities
 A
28 Liabilities of discontinued operations
29 Total current liabilities
30 Long-term debt
31 Pension benefit obligations
32 Postretirement benefit obligations
33 Noncurrent deferred tax liabilities
34 Other taxes payable
35 Other noncurrent liabilities
36 Total liabilities
37

38 Preferred stock, without par value, at stated value; 27 shares authorized; issued: 2015—967;
2014—1,112
39 Common stock, $0.05 par value; 12,000 shares authorized; issued: 2015—8,956; 2014—
8,902
40 Additional paid-in capital
41 Employee benefit trusts
42 Treasury stock, shares at cost: 2015—1,680; 2014—1,327
43 Retained earnings
44 Accumulated other comprehensive loss
45 Total shareholders’ equity
46 Equity attributable to noncontrolling interests
47 Total equity
48
49 Total liabilities and equity
 A
50
51 PharmaCorp
52 Consolidated Statements of Income (USD $)
53 In Millions, except Per Share data, unless otherwise specified
54
55 Revenues
56 Costs and expenses:
57 Cost of sales
58 Selling, informational and administrative expenses
59 Research and development expenses
60 Amortization of intangible assets
61 Restructuring charges and certain acquisition-related costs
62 Other deductions––net
63 Income from continuing operations before provision for taxes on income
64 Provision for taxes on income
65 Income from continuing operations
66 Discontinued operations:
67 Income/(loss) from discontinued operations––net of tax
68 Gain/(loss) on sale of discontinued operations––net of tax
69 Discontinued operations––net of tax
70 Net income before allocation to noncontrolling interests
71
Less: Net income attributable to noncontrolling interests
72 Net income attributable to PharmaCorp Inc.

73
Earnings per common share––basic:
74 Income from continuing operations attributable to PharmaCorp Inc. common shareholders
 A
75 Discontinued operations––net of tax
76 Net income attributable to PharmaCorp Inc. common shareholders
77 Earnings per common share––diluted:
78 Income from continuing operations attributable to PharmaCorp Inc. common shareholders
79 Discontinued operations––net of tax
80 Net income attributable to PharmaCorp Inc. common shareholders
81 Weighted-average shares––basic
82 Weighted-average shares––diluted
83 Cash dividends paid per common share
84
 A
85
86 PharmaCorp
87 Consolidated Statements of Cash Flows (USD $)
88 In Millions, unless otherwise specified
89
Operating Activities
90 Net income before allocation to noncontrolling interests
91 Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
92 Depreciation and amortization
93 Share-based compensation expense
94 Asset write-offs and impairment charges
95 (Gain)/loss on sale of discontinued operations
96 Deferred taxes from continuing operations
97 Deferred taxes from discontinued operations
98 Benefit plan contributions (in excess of)/less than expense
99 Other non-cash adjustments, net
100 Other changes in assets and liabilities, net of acquisitions and divestitures:
101 Accounts receivable
102 Inventories
103 Other assets
104 Accounts payable
105 Other liabilities
106 Other tax accounts, net
107 Net cash provided by operating activities
108 Investing Activities
109 Purchases of property, plant and equipment
110 Purchases of short-term investments
111 Proceeds from redemptions and sales of short-term investments
 A
112 Net proceeds from redemptions and sales of short-term investments with original maturities o
113 Purchases of long-term investments
114 Proceeds from redemptions and sales of long-term investments
115 Acquisitions, net of cash acquired
116 Proceeds from sale of businesses
117 Other investing activities
118 Net cash provided by/(used in) investing activities
119 Financing Activities
120 Proceeds from short-term borrowings
121 Principal payments on short-term borrowings
122 Net payments on short-term borrowings with original maturities of 90 days or less
123 Principal payments on long-term debt
124 Purchases of common stock
125 Cash dividends paid
126 Other financing activities
127 Net cash used in financing activities
128 Effect of exchange-rate changes on cash and cash equivalents
129 Net increase/(decrease) in cash and cash equivalents
130 Cash and cash equivalents, beginning
131 Cash and cash equivalents, ending
132 Cash paid during the period for:
133 Income taxes
134 Interest
 B D E F
1
2
3
Dec. 31, 2015 Dec. 31, 2014
4
5 (unaudited) (audited)
6
7 $10,389 $3,182
8 22,319 23,270
9 12,378 13,058
10 7,063 6,610
11 9,196 9,380
12 70 5,317
13 61,415 60,817
14 14,149 9,814
15 14,461 15,921
16 44,672 44,569
17 46,013 51,184
18 5,088 5,697
19 185,798 188,002
20
21

22 6,424 4,016
23 4,264 3,678
24 1,734 1,796
25 1,010 1,009
26 2,046 2,120
27 13,141 15,066
 B D E F
28 0 1,224
29 28,619 28,909
30 31,036 34,926
31 7,830 6,355
32 3,493 3,344
33 21,593 18,861
34 6,610 6,886
35 4,939 6,100
36 104,120 105,381
37

38 39 45

39 448 445
40 72,608 71,423
41 -1 -3
42 -40,121 -31,801
43 54,240 46,210
44 -5,953 -4,129
45 81,260 82,190
46 418 431
47 81,678 82,621
48
49 185,798 188,002
 B D E F
50
51
52
53 Dec. 31, 2015 Dec. 31, 2014 Dec. 31, 2013
54
55 $58,986 $65,259 $65,165
56
57 11,334 14,076 14,788
58 16,616 18,832 18,973
59 7,870 9,074 9,483
60 5,175 5,544 5,364
61 1,880 2,930 3,145
62 4,031 2,499 3,941
63 12,080 12,304 9,471
64 2,562 3,909 1,153
65 9,518 8,395 8,318
66
67 297 350 -19
68 4,783 1,304 -11
69 5,080 1,654 -30
70 14,598 10,049 8,288

71 28 40 31
72 $14,570 $10,009 $8,257
73

74 $1.27 $1.07 $1.03

 B D E F
75 $0.68 $0.21 $0.00
76 $1.96 $1.28 $1.03
77
78 $1.26 $1.06 $1.03
79 $0.68 $0.21 $0.00
80 $1.94 $1.27 $1.02
81 7,442 7,817 8,036
82 7,508 7,870 8,074
83 $0.88 $0.80 $0.72
84
 B D E F
85
86
87
88 Dec. 31, 2015 Dec. 31, 2014 Dec. 31, 2013
89 (unaudited) (audited) (audited)
90 $14,598 $10,049 $8,288
erests to net cash
91 provided by operating activities:
92 7,611 8,907 8,399
93 481 419 405
94 1,299 1,198 3,486
95 -7,123 -1,688 11
96 739 307 2,109
97 1,459 147 -156
98 135 -1,769 -677
99 -203 -172 -49
100
101 275 -66 -608
102 -631 1,084 2,917
103 83 701 -818
104 579 -367 -301
105 -3,438 1,508 1,114
106 1,190 -18 -12,666
107 17,054 20,240 11,454
108
109 -1,327 -1,660 -1,513
110 -24,018 -18,447 -11,082
111 25,302 14,176 5,699
 B D E F
112 1,459 10,874 5,950
113 -11,145 -4,620 -4,128
114 4,990 2,147 4,737
115 -1,050 -3,282 -273
116 11,850 2,376 0
117 93 279 118
118 6,154 1,843 -492
119
120 7,995 12,810 6,400
121 -3 -3,826 -9,249
122 -8,204 -7,540 -1,297
123 -1,513 -6,986 -6
124 -8,228 -9,000 -1,000
125 -6,534 -6,234 -6,088
126 488 169 66
127 -15,999 -20,607 -11,174
128 -2 -29 -31
129 7,207 1,447 -243
130 3,182 1,735 1,978
131 10,389 3,182 1,735
132
133 2,430 2,938 11,775
134 $1,873 $2,085 $2,155
 G
75
76
77
78
79
80
81
82
83
84
 G
85
86
87
88

89

90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
PharmaCorpOperatingSegments

We manage our operations through five operating segments —Primary Care; Specialty Care and Oncology; Established Products and
Emerging Markets; Animal Health; and Consumer Healthcare. As of the third quarter of 2012, the Animal Health and Consumer Healthcare
business units are no longer managed as a single operating segment. Each operating segment has responsibility for its commercial
activities and for certain research and development activities r e l a t e d to in-line products and in-process research and development
(IPR&D) projects that generally have achieved p r o o f - o f - c o n c e p t .

On November 30, 2015, we completed the sale of our Nutrition business to Choco and recognized a gain on the sale of this business in
Gain/(loss) on sale of discontinued operations––net of tax in the consolidated statement of income for the year ended December 31, 2015.
The operating results of this business are reported as Income/(loss) from discontinued operations––net of tax in the consolidated
statements of income for all periods presented.

We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Generally,
products a r e transferred to the Established Products business unit in the beginning of the fiscal year following loss of patent protection or
marketing exclusivity.

A description of each of our five operating segments f o l l o w s :

• Primary Care operating segment —includes revenues from human prescription pharmaceutical products primarily prescribed by
primary-care physicians, and may include products in the following therapeutic and disease areas: Alzheimer’s disease,
cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, genitourinary, major depressive disorder, pain,
respiratory and smoking cessation. All revenues for these products are allocated to the Primary Care business unit, except
those generated i n emerging markets and those that are managed by the Established Products business unit.

• Specialty Care and Oncology operating segment —comprises the Specialty Care business unit and the Oncology business unit.

· Specialty Care—includes revenues from human prescription pharmaceutical products primarily prescribed by physicians
who are specialists, and may include products in the following therapeutic and disease areas: anti-infectives, endocrine
disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and
vaccines. All revenues for these products are allocated to t h e Specialty Care business unit, except those generated in
emerging markets and those that are managed by the Established Products business u n i t .

· Oncology—includes revenues from human p r e s c r i p t i o n p h a r m a c e u t i c a l products addressing oncology and o n c o l o g y - r e l a t e d

illnesses. All revenues for these products are allocated to the Oncology business unit, except those generated in
emerging markets and those t h a t are managed by the Established Products business unit.

• Established Products and Emerging Markets operating s e g m e n t —comprises the Established Products business unit and the
Emerging Markets business u n i t .

· Established Products—includes revenues from human prescription pharmaceutical products that have lost patent
protection or marketing exclusivity in certain countries and/or regions. Typically, products are transferred to this business
unit in the beginning of the fiscal year following loss of patent protection or marketing exclusivity. However, in certain
situations, products may be transferred to this business unit at a different point than the beginning of the fiscal year
following loss of patent protection or marketing exclusivity in order to maximize their value. This business unit also
excludes revenues generated in emerging markets.
· Emerging M a r k e t s — i n c l u d e s revenues from all human prescription pharmaceutical products sold in emerging markets,
including Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and
Central Europe.
PharmaCorpGeographicInformation

Revenues exceeded $500 million in each of 16 countries outside the U.S. in 2015 and 2014, and in each of 17 countries outside the U.S. in 2013. Th
and Japan were the only countries to contribute more than 10% of total revenue in 2015. The U.S. was the only country to contribute more than 10
total revenue in 2014 and 2013.

The following table provides revenues by geographic area:

Year Ended December 31,

(MILLIONS OF DOLLARS) 2015 2014 2013

Revenues

United States $ 23,086 $ 26,933 $ 28,855

Developed Europe 13,375 16,099 16,156

Developed Rest of World 10,554 10,975 9,891

Emerging Markets 11,971 11,252 10,263

Revenues $ 58,986 $ 65,259 $ 65,165

Revenues $ 58,986 $ 65,259 $ 65,165
utside the U.S. in 2013. The U.S.
o contribute more than 10% of
PharmaCorp.
Long-Term Debt
The following table provides the components of senior unsecured long-term debt:

As of December 31,

Maturity Date 2015 2014

6.20% March 2022 $ 3,327 $ 3,248

5.35% Mar-18 3,065 3,069

7.20% Mar-42 2,903 2,948

4.75% Jun-19 2,638 2,583

5.75% Jun-24 2,634 2,581

3.625% (At
December 31,
2015, the note
has been
Jun-16 — 2,392
reclassified to
Current portion
of long-term
debt.)

6.50% Jun-41 2,407 2,306

5.95% Apr-40 2,086 2,088

5.50% February 2017 1,832 1,893

5.50% (At
December 31,
2015, the note
Mar-16 — 1,564
had been called
and is no longer
outstanding.)

4.55% May-20 1,384 1,325

 4.55% May-20 1,384 1,325

4.75% December 2017 1,284 1,266

5.50% Feb-19 1,048 1,061

6.51% 2028 3,403 3,435

5.28% 2019 2,254 2,302

2.48% 2018 771 865

Long-term
$ 31,036 $ 34,926
debt
20-F FILINGS
NOVARTELL GROUP CONSOLIDATED FINANCIAL STATEMENTS
CONSOLIDATED BALANCE SHEETS
(At December 31, 2015 and 2014)

2015
(unaudited)
$m
Assets
Non-current assets
Property, plant & equipment
Goodwill
Intangible assets other than goodwill
Investments in associated companies
Deferred tax assets
Financial assets
Other non-current assets

Total non-current assets

Current assets
Inventories
Trade receivables
Marketable securities and derivative financial instruments
Cash and cash equivalents
Other current assets

Total current assets

Total assets

Equity and liabilities

Equity
Share capital
Treasury shares
Reserves

Issued share capital and reserves attributable to novartell AG

shareholders
Non-controlling interests

Total equity
Liabilities
Non-current liabilities
Financial debt
Deferred tax liabilities
Provisions and other non-current liabilities

Total non-current liabilities

Current liabilities
Trade payables
Financial debt and derivative financial instruments
Current income tax liabilities
Provisions and other current liabilities

Total current liabilities

Total liabilities

Total equity and liabilities

NOVARTELL GROUP CONSOLIDATED FINANCIAL STATEMENTS
CONSOLIDATED INCOME STATEMENTS
(For the years ended December 31, 2015, 2014 and 2013)

2015
(unaudited)
$m
Net sales
Other revenues
Cost of goods sold

Gross profit
Marketing & Sales
Research & Development
General & Administration
Other income
Other expense

Operating income
Income from associated companies
Interest expense
Other financial income and expense

Income before taxes

Taxes

Net income

Attributable to:
Shareholders of novartell AG
Non-controlling interests
Basic earnings per share ($)
Diluted earnings per share ($)
NOVARTELLGROUP CONSOLIDATED FINANCIAL STATEMENTS
CONSOLIDATED CASH FLOW STATEMENTS
(For the years ended December 31, 2015, 2014 and 2013)

2015
(unaudited)
$m
Net income
Reversal of non-cash items
Dividends received from associated companies and others
Interest received
Interest paid
Other financial receipts
Other financial payments
Taxes paid

Cash flows before working capital and provision changes

Restructuring payments and other cash payments from provisions

Change in net current assets and other operating cash flow items

Cash flows from operating activities

Purchase of property, plant & equipment

Proceeds from sales of property, plant & equipment
Purchase of intangible assets
Proceeds from sales of intangible assets
Purchase of financial assets
Proceeds from sales of financial assets
Purchase of other non-current assets
Proceeds from sales of other non-current assets
Acquisitions of interests in associated companies
Acquisitions and divestments of businesses
Purchase of marketable securities
Proceeds from sales of marketable securities

Cash flows used in investing activities

Acquisition of treasury shares

Disposal of treasury shares
Increase in non-current financial debt
Repayment of non-current financial debt
Change in current financial debt
Proceeds from issuance of share capital to third parties
Acquisition of non-controlling interests
Dividends paid to non-controlling interests and other financing cash
flows
Dividends paid to shareholders of novartell AG

Cash flows used in financing activities

Net effect of currency translation on cash and cash equivalents

Net change in cash and cash equivalents

Cash and cash equivalents at January 1

Cash and cash equivalents at December 31

 2015 2014
(unaudited) (audited)
$m $m

16,939 15,627
31,090 29,943
30,331 31,969
8,840 8,622
7,390 5,857
1,117 938
505 456

96,212 93,412

6,744 5,930
10,051 10,323
2,567 1,366
5,552 3,709
3,090 2,756

28,004 24,084

124,216 117,496

1,001 1,016
(92) (121)
68,184 64,949

69,093 65,844

126 96

69,219 65,940
 13,781 13,855
7,286 6,761
9,879 7,792

30,946 28,408

5,593 4,989
5,945 6,374
2,070 1,706
10,443 10,079

24,051 23,148

54,997 51,556

124,216 117,496
 2015 2014 2013
(unaudited) (audited) (audited)
$m $m $m
56,673 58,566 50,624
888 809 937
(18,756) 18,983 (14,488)

38,805 40,392 37,073

(14,353) (15,079) (13,316)
(9,332) (9,583) (9,070)
(2,937) (2,970) (2,481)
1,187 1,354 1,234
(1,859) (3,116) (1,914)

11,511 10,998 11,526

552 528 804
(724 ) (751 (692
(96 ) (2 64

11,243 10,773 11,702

(1,625 ) (1,528 (1,733

9,618 9,245 9,969

9,505 9,113 9,794

113 132 175
3.93 3.83 4.28
3.89 3.78 4.26
 2015 2014 2013
(unaudited) (audited) (audited)
$m $m $m
9,618 9,245 9,969
7,838 9,300 6,162
426 404 571
49 66 170
(594 ) (640 ) (525
214
(22 ) (47 ) (145
(2,022 ) (2,435 ) (2,616

15,507 15,893 13,586

(1,173 ) (1,471 ) (1,281

(140 ) (113 ) 1,762

14,194 14,309 14,067

(2,698 ) (2,167 ) (1,678

92 61 36
(370 ) (220 ) (554
163 643 545
(180 ) (139 ) (124
221 59 66
(57 ) (48 ) (15
18 5 3
(12 )
(1,741 ) (569 ) (26,666
(1,639 ) (1,750 ) (40,569
516 3,345 53,200

(5,675 ) (792 ) (15,756

(505 ) (3,628 ) (311

414 159 711
 1,979 281 5,674
(704 ) (28 ) (5
(1,737 ) (3,054 ) 2,610
4 19
(6 ) (3,187 ) (32
(86 ) (203 ) (64

(6,030 ) (5,368 ) (4,486

(6,675 ) (15,024 ) 4,116

(1 ) (103 ) (2

1,843 (1,610 ) 2,425

3,709 5,319 2,894

5,552 3,709 5,319

)

)
)

)
)

)
)

)
)

)
20-F FILINGS
AstraZoro
Consolidated Balance Sheet
at 31 December

2015
(unaudited)
$m
Assets

Non-current assets

Property, plant and equipment

6,089
Goodwill 9,898
Intangible assets 16,448
Derivative financial
instruments 389
Other investments 199
Other receivables 352
Deferred tax assets 1,111
34,486

Current assets
Inventories 2,061
Trade and other receivables 7,629
Other investments 823
Derivative financial
instruments 31
Income tax receivable 803
Cash and cash equivalents 7,701
19,048
Total assets 53,534

Liabilities
Current liabilities
Interest-bearing loans and
borrowings (901 )
Trade and other payables (9,221 )
Derivative financial
instruments (3 )
Provisions (916 )
Income tax payable (2,862 )
(13,903 )
Non-current liabilities
Interest-bearing loans and
borrowings (9,409 )
Deferred tax liabilities (2,576 )

Retirement benefit obligations

(2,265 )
Provisions (428 )
Other payables (1,001 )

(15,679 )
Total liabilities (29,582 )
Net assets 23,952

Equity

Capital and reserves

attributable to equity
holders of the Company
Share capital 312
Share premium account 3,504
Capital redemption reserve 153
Merger reserve 433
Other reserves 1,374
Retained earnings 17,961
23,737
Non-controlling interests 215
Total equity 23,952
AstraZoro
Consolidated Statements of Income
for the year ended 31 December
2015

(unaudited)
$m
Revenue 27,973
Cost of sales (5,393 )
Gross profit 22,580
Distribution costs (320 )
Research and development
expense (5,243 )
Selling, general and
administrative costs (9,839 )
Profit on disposal of
subsidiary –
Other operating income and
expense 970
Operating profit 8,148
Finance income 528
Finance expense (958 )
Profit before tax 7,718
Taxation (1,391 )
Profit for the period 6,327

Other comprehensive
income:
Foreign exchange arising on
consolidation 106
Foreign exchange differences
on borrowings designated in
net investment hedges (46 )
Fair value movements on
derivatives designated in net
investment hedges 76
Amortisation of loss on cash
flow hedge 1
 Net available for sale gains
taken to equity 72
Actuarial loss for the period (85 )
Income tax relating to
components of other
comprehensive income (46 )
Other comprehensive
income for the period, net of
tax 78
Total comprehensive income
for the period 6,405

Profit attributable to:

Owners of the Parent 6,297
Non-controlling interests 30

Total comprehensive income

attributable to:
Owners of the Parent 6,395
Non-controlling interests 10

Basic earnings per $0.25

Ordinary Share $4.99
Diluted earnings per $0.25
Ordinary Share $4.98
Weighted average number of
Ordinary Shares in issue
(millions) 1,261
Diluted weighted average
number of Ordinary Shares in
issue (millions) 1,264

Dividends declared and paid

in the period 3,619
All activities were in respect of continuing operations.
$m means millions of US dollars.
AstraZoro
Consolidated Statements of Cash Flows
for the year ended 31 December
2015
(unaudited)
$m

Cash flows from operating

activities
Profit before tax 7,718
Finance income and expense 430
Depreciation, amortisation
and impairment 2,518
Decrease/(increase) in trade
and other receivables 755
(Increase)/decrease in
inventories (150 )
(Decrease)/increase in trade
and other payables and
provisions (1,311 )
Profit on disposal of
subsidiary –
Non-cash and other
movements (424 )
Cash generated from
operations 9,536
Interest paid (545 )
Tax paid (2,043 )
Net cash inflow from
operating activities 6,948

Cash flows from investing

activities
Acquisitions of business
operations (1,187 )
Movement in short-term
investments and fixed
deposits 3,619
Purchase of property, plant
and equipment (672 )
Disposal of property, plant
and equipment 199
Purchase of intangible assets (3,947 )
Disposal of intangible assets –
Purchase of non-current asset
investments (46 )
Disposal of non-current asset
investments 43
Net cash received on disposal
of subsidiary –
Dividends received 7
Interest received 145
Payments made by
subsidiaries to non-controlling
interests (20 )
Net cash outflow from
investing activities (1,859 )
Net cash inflow before
financing activities 5,089

Cash flows from financing

activities
Proceeds from issue of share
capital 429
Repurchase of shares (2,635 )
Repayment of obligations
under finance leases (17 )
Issue of loans 1,980
Repayment of loans (1,750 )
Dividends paid (3,665 )
Hedge contracts relating to
dividend payments 48
Movement in short-term
borrowings 687
Net cash outflow from
financing activities (4,923 )
Net increase/(decrease) in
cash and cash equivalents in
the period 166
Cash and cash equivalents at
the beginning of the period 7,434
Exchange rate effects (4 )
Cash and cash equivalents
at the end of the period 7,596
 2014 2013
(audited) (audited)
$m $m

6,425 6,957
9,862 9,871
10,980 12,158

342 324
201 211
– –
1,514 1,475
29,324 30,996

1,852 1,682
8,754 7,847
4,248 1,482

25 9
1,056 3,043
7,571 11,068
23,506 25,131
52,830 56,127

(1,990 ) (125 )
(8,975 ) (8,661 )
 (9 ) (8 )
(1,388 ) (1,095 )
(3,390 ) (6,898 )
(15,752 ) (16,787 )

(7,338 ) (9,097 )
(2,735 ) (3,145 )

(2,674 ) (2,472 )
(474 ) (843 )
(385 ) (373 )

(13,606 ) (15,930 )
(29,358 ) (32,717 )
23,472 23,410

323 352
3,078 2,672
139 107
433 433
1,379 1,377
17,894 18,272
23,246 23,213
226 197
23,472 23,410
 2014 2013

(audited) (audited)
$m $m
33,591 33,269
(6,026 ) (6,389 )
27,565 26,880
(346 ) (335 )

(5,523 ) (5,318 )

(11,161 ) (10,445 )

1,483 –

777 712
12,795 11,494
552 516
(980 ) (1,033 )
12,367 10,977
(2,351 ) (2,896 )
10,016 8,081

(60 ) 26

24 101

– –

2 1
 31 4
(741 ) (46 )

198 (61 )

(546 ) 25

9,470 8,106

9,983 8,053
33 28

9,428 8,058
42 48

$7.33 $5.60

$7.30 $5.57

1,361 1,438

1,367 1,446

3,752 3,494
 2014 2013
(audited) (audited)
$m $m

12,367 10,977
428 517

2,550 2,741

(1,108 ) 10

(256 ) 88

467 (16 )

(1,483 ) –

(597 ) (463 )

12,368 13,854
(548 ) (641 )
(3,999 ) (2,533 )

7,821 10,680

– (348 )

(2,743 ) (125 )
 (839 ) (791 )

102 83
(458 ) (1,390 )
– 210

(11 ) (34 )

– 5

1,772 –
– –
171 174

(16 ) (10 )

(2,022 ) (2,226 )

5,799 8,454

409 494
(6,015 ) (2,604 )

– –
– –
– (1,741 )
(3,764 ) (3,361 )

3 (114 )

46 (8 )

(9,321 ) (7,334 )
(3,522 ) 1,120

10,981 9,828
(25 ) 33

7,434 10,981